Trovagene (TROV) Misses Q2 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. ZETA
10. DAL

Go back to Trovagene (TROV) Misses Q2 EPS by 17c

Trovagene, Inc. Announces Second Quarter 2015 Financial Results

August 10, 2015 4:05 PM EDT

SAN DIEGO, Aug. 10, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2015.

"Our pilot commercial team has gained impressive traction in the field, delivering stronger than expected participation by oncologists in our Clinical Experience Program," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Additionally, we continue to demonstrate in clinical studies the utility of our Precision Cancer Monitoring platform to detect and monitor... More